Project description
Earlier diagnosis of Alzheimer's by a new genetic assay
Early diagnosis of Alzheimer’s disease relies on testing that is not easily applicable to the broader population. However, early diagnosis for both families and health providers are crucial as its incidence is expected to triple by 2050 from the current estimate of 45 million. The variaTECT method uses 130K single nucleotide polymorphism (SNP) testing and software to analyse DNA extracts from blood or saliva samples. It is 85 % accurate with significant cost savings for patients and revenue for genetic laboratories. The project will upgrade variaTECT’s design to determine dementia types and increase production capacity, aiming for clinical trials for an in-vitro diagnostic device.
Fields of science
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- humanitiesartsarchitectural design
- natural sciencesbiological sciencesgeneticsnucleotides
- engineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imaging
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1
Coordinator
M2 2AN Manchester
United Kingdom
See on map